Headache Impact Test-6
Also known as: HIT-6, Headache Impact Test, HIT
The HIT-6 is a brief, validated measure of headache impact on daily functioning and quality of life. Developed by Mark Kosinski and colleagues in 2003, this 6-item questionnaire quantifies how headache (migraine or other types) affects work, social activities, sleep, and emotional well-being. It is widely used in headache research, clinical trials, and practice to assess disease burden and treatment benefit.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The HIT-6 is indicated for assessing headache burden in any patient with frequent or disabling headaches. Use cases include baseline assessment to quantify functional impact and guide preventive therapy decisions, monitoring during treatment (preventive medications, Botox, CGRP antagonists, lifestyle interventions) to assess patient-experienced benefit, outcome measurement in headache trials as a primary or co-primary endpoint, and quality improvement in neurology and primary care. The HIT-6 is valuable for episodic migraine, chronic migraine, tension-type headache, and other headache types. A shorter version (HIT-4) exists for very brief screening. The HIT-6 is less suitable for acute headache assessment (use pain scales) or non-headache populations.
Strengths & limitations
- Exceptional brevity—6 items, 1-2 minute completion, compatible with any clinical setting; increases likelihood of routine use
- Strong psychometric properties—extensively validated across headache types (migraine, tension, cluster, medication overuse) with demonstrated internal consistency (Cronbach's α 0.80-0.90), test-retest reliability (ICC 0.80), and responsiveness to preventive therapies
- Clinically meaningful cutoffs—scores ≥56 clearly indicate substantial impact warranting preventive treatment, guiding actionable decisions
- Validated across age and headache types—applicable to episodic and chronic migraine, tension-type headache, and mixed presentations
- Free and universally accessible—no licensing restrictions; downloadable forms and scoring from headache societies (American Headache Society, International Headache Society)
- Responsive to treatment—sensitive to preventive medication efficacy, CGRP antagonists, Botox, and lifestyle interventions
- Does not measure headache frequency or intensity directly—HIT-6 assesses functional impact, not pain severity or attack frequency; must ask separately about headache characteristics
- Does not diagnose headache type—measures impact of presumed headache; clinical history and criteria needed to classify migraine vs. tension-type vs. other types
- Limited correlation with pain intensity—HIT-6 correlates weakly to moderately with headache severity (r = 0.30-0.50); functional impact is independent of pain and depends on frequency, disability tolerance, and coping
- Potential response bias—patients may over-report impact if seeking preventive therapy or validation; conversely, may minimize impact if fearful of medication side effects
- Does not assess specific headache-related complications—does not distinguish migraine aura, medication overuse headache, or comorbid conditions (depression, anxiety)
Frequently asked
A patient has HIT-6 52 (some impact) but gets migraines twice weekly. Should I initiate preventive therapy?
HIT-6 52 is borderline; consider preventive therapy if: (1) frequency ≥4 days/month (this patient meets criteria at 8-9 days/month—strong indication); (2) individual attacks disable the patient significantly; (3) acute medication side effects or overuse concerns exist. Initiate preventive therapy (topiramate, propranolol, CGRP antagonist) and re-assess HIT-6 at 4-8 weeks. Expect HIT-6 to improve as frequency decreases.
HIT-6 didn't improve despite preventive medication. What might explain this?
Possible explanations: (1) medication non-adherence; (2) insufficient treatment duration (most preventives require 4-8 weeks to show benefit); (3) inadequate dosing; (4) comorbid conditions (depression, anxiety, sleep apnea) independent of preventive therapy; (5) medication overuse headache (if taking acute medication >10 days/month); (6) need for combination therapy or different preventive agent. Assess adherence, duration, dose, and comorbidities before changing therapy.
What constitutes clinically meaningful HIT-6 change?
A 5-6 point reduction represents minimum clinically important difference. Improvement from HIT-6 60 to 54 indicates meaningful functional gain. Larger improvements (10+ points) represent substantial benefit, often accompanying preventive therapy initiation in high-impact migraines.
Is HIT-6 appropriate for tension-type headache or just migraine?
HIT-6 applies to all headache types, including tension-type, cluster, and medication overuse headache. However, tension-type headaches typically generate lower HIT-6 than migraine despite similar frequency (due to lower disability per attack); use condition-specific reference values when available for contextual interpretation.
Sources
- Kosinski, M., Bayliss, M. S., Bjorner, J. B., Ware, J. E., Garber, W. H., Batenhorst, A., & Tepper, S. (2003). A six-item short-form survey for measuring headache impact: The HIT-6. Quality of Life Research, 12(8), 963-974. DOI: 10.1023/A:1026119331193 ↗
- Yang, M., Rendas-Baum, R., Varon, S. F., & Kosinski, M. (2011). Validation of the Headache Impact Test (HIT-6) across episodic and chronic migraine. Cephalalgia, 31(3), 357-367. DOI: 10.1177/0333102410379890 ↗
- Lipton, R. B., Dodick, D. W., Silberstein, S. D., Saper, J. R., Aurora, S. K., Pearlman, S. H., ... & Goadsby, P. J. (2007). Topiramate for episodic migraine prevention: A randomized, double-blind, placebo-controlled trial. Headache, 47(2), 170-180. link ↗
How to cite this page
ScholarGate. (2026, June 3). Headache Impact Test-6. ScholarGate. https://scholargate.app/en/health-outcomes/headache-impact-test
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- DLQIHealth Outcomes↔ compare
- EORTC QLQ-C30Health Outcomes↔ compare
- FIQHealth Outcomes↔ compare
- PDQ-39Health Outcomes↔ compare